Zenas BioPharma shares rise nearly 8% in market debut
Sept 13 (Reuters) - Shares of Bristol-Myers Squibb-backed Zenas BioPharma ZBIO.O rose nearly 8% in their Nasdaq debut on Friday, in a sign of recovery for the U.S. IPO market in 2024 after two sub par years. (Reporting by Pritam Biswas in Bengaluru; Editing by Janane Venkatraman) ((Pritam.Biswas@thomsonreuters.com;))
Recent news on Zenas BioPharma
See all newsBrief: Zenas Biopharma Announces Upcoming Presentations Of Obexelimab Data In Igg4-Related Disease At The Igg4ward! 6Th International Symposium On Igg4-Related Disease And Acr Convergence 2026
Brief: Zenas BioPharma Files For Offering Of Up To 7.0 Million Shares Of Common Stock By The Selling Stockholder - SEC Filing
Zenas BioPharma, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Zenas Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Zenas Biopharma Says Phase 3 Indigo Trial Of Obexelimab Meets Primary And All Key Secondary Endpoints